Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1 PK and Safety in Obese/Borderline Hypertensive Subjects
NCT03903302Phase 1Completed
- Sponsor
- Cereno Scientific AB
- Start
- Oct 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of bisantrene in thrombosis (4 arms), sponsored by Cereno Scientific AB. Primary endpoint: Pharmacokinetics of CS1 in plasma up to 4 weeks. Started Oct 2017; status: completed.
02
Drugs
bisantrene
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT03903302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903302.